Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins
University Hospital of Zurich · Center for Biologics Evaluation and Research · +1 more institution
Abstract
Hemolysis occurs in many hematologic and nonhematologic diseases. Extracellular hemoglobin (Hb) has been found to trigger specific pathophysiologies that are associated with adverse clinical outcomes in patients with hemolysis, such as acute and chronic vascular disease, inflammation, thrombosis, and renal impairment. Among the molecular characteristics of extracellular Hb, translocation of the molecule into the extravascular space, oxidative and nitric oxide reactions, hemin release, and molecular signaling effects of hemin appear to be the most critical. Limited clinical experience with a plasma-derived haptoglobin (Hp) product in Japan and more recent preclinical animal studies suggest that the natural Hb…
Citation impact
- FWCI
- 15.89
- Percentile
- 100%
- References
- 103
Authors
5- DJDominik J. SchaerCorresponding
University Hospital of Zurich
- PWPaul W. Buehler
Center for Biologics Evaluation and Research
- AIAbdu I. Alayash
Center for Biologics Evaluation and Research
- JDJohn D. Belcher
University of Minnesota Medical Center
- GMGregory M. Vercellotti
University of Minnesota Medical Center
Topics & keywords
- Hemopexin
- Hemin
- Hemolysis
- Haptoglobin
- Hemoglobin
- Sepsis
- Medicine
- Immunology
Funding
- NSNational Science FoundationAward: 310030
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAwards: 310030/120658, 31003A, 31003A/138500, 138500, 120658, 310030
- KFKommission für Technologie und Innovation
- UZUniversität Zürich
- NINational Institutes of HealthAwards: HL115467-01, HL55552, HL110900
- UFU.S. Food and Drug Administration
- NHNational Heart, Lung, and Blood InstituteAwards: HL110900, P01 HL55552, R01 HL115467-01